NASDAQ:TPTXTurning Point Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Turning Point Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $46.96 +1.27 (+2.78 %) (As of 04/8/2020 12:08 PM ET) Add Compare Share Today's Range$45.75Now: $46.96▼$47.4950-Day Range$32.02MA: $45.78▼$61.0852-Week Range$24.21Now: $46.96▼$67.54Volume2,853 shsAverage Volume396,011 shsMarket Capitalization$1.69 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTurning Point Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.25, Turning Point Therapeutics has a potential upside of 26.2% from its current price of $46.96.Amount of Analyst CoverageTurning Point Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesTurning Point Therapeutics has received 42 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTurning Point Therapeutics has received 34 “underperform” votes. (Add your “underperform” vote.)Community SentimentTurning Point Therapeutics has received 55.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Turning Point Therapeutics and other stocks. Vote “Outperform” if you believe TPTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TPTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTurning Point Therapeutics does not currently pay a dividend.Dividend GrowthTurning Point Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turning Point Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,702,188.00 in company stock.Percentage Held by Institutions78.56% of the stock of Turning Point Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Turning Point Therapeutics are expected to grow by 26.69% in the coming year, from ($2.96) to ($3.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turning Point Therapeutics is -7.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turning Point Therapeutics is -7.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurning Point Therapeutics has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.71 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TPTX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.tptherapeutics.com/ Phone858-926-5251Debt Debt-to-Equity Ratio0.01 Current Ratio29.57 Quick Ratio29.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.28 per share Price / Book4.16Profitability EPS (Most Recent Fiscal Year)($2.99) Net Income$-72,130,000.00 Net MarginsN/A Return on Equity-28.49% Return on Assets-23.82%Miscellaneous Employees50 Outstanding Shares35,924,000Market Cap$1.69 billion Next Earnings Date5/29/2020 (Estimated) OptionableNot Optionable Receive TPTX News and Ratings via Email Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TPTX Rates by TradingView Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions How has Turning Point Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TPTX stock has increased by 15.8% and is now trading at $46.96. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Turning Point Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Turning Point Therapeutics. When is Turning Point Therapeutics' next earnings date? Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Turning Point Therapeutics. How were Turning Point Therapeutics' earnings last quarter? Turning Point Therapeutics (NASDAQ:TPTX) released its quarterly earnings data on Monday, March, 16th. The company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.09. View Turning Point Therapeutics' earnings history. What price target have analysts set for TPTX? 8 equities research analysts have issued 12-month price objectives for Turning Point Therapeutics' stock. Their forecasts range from $48.00 to $72.00. On average, they expect Turning Point Therapeutics' share price to reach $59.25 in the next year. This suggests a possible upside of 26.2% from the stock's current price. View analysts' price targets for Turning Point Therapeutics. Has Turning Point Therapeutics been receiving favorable news coverage? News coverage about TPTX stock has trended very negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Turning Point Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutTurning Point Therapeutics. Who are some of Turning Point Therapeutics' key competitors? Some companies that are related to Turning Point Therapeutics include ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Mirati Therapeutics (MRTX) and Emergent Biosolutions (EBS). What other stocks do shareholders of Turning Point Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include Axsome Therapeutics (AXSM), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Immunomedics (IMMU), Intel (INTC), Sarepta Therapeutics (SRPT), Voyager Therapeutics (VYGR), AbbVie (ABBV), Enterprise Products Partners (EPD) and Energy Transfer LP Unit (ET). Who are Turning Point Therapeutics' key executives? Turning Point Therapeutics' management team includes the following people: Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor RelationsMs. Annette C. North, Exec. VP, Gen. Counsel & Company Sec. When did Turning Point Therapeutics IPO? (TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Turning Point Therapeutics' stock symbol? Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX." How do I buy shares of Turning Point Therapeutics? Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Turning Point Therapeutics' stock price today? One share of TPTX stock can currently be purchased for approximately $46.96. How big of a company is Turning Point Therapeutics? Turning Point Therapeutics has a market capitalization of $1.69 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Turning Point Therapeutics employs 50 workers across the globe. View additional information about Turning Point Therapeutics. What is Turning Point Therapeutics' official website? The official website for Turning Point Therapeutics is http://www.tptherapeutics.com/. How can I contact Turning Point Therapeutics? Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Certificate of Deposit (CD)
